Get started

Aspen

UPDATE: Target Reached Aspen R206.03 - Next target higherSymmetrical Triangle was a a text book trade. The previous trend was up. Price broke above the apex 3/4s in and the momentum continued up. We had further indicators of confirmation for upside to come. Price>20 Price>200 Target 1 R206.03 So what now? Well we can expect somewhat a consolidation, and a potential Cup and Handle to form. Then we have the next target above R221. It might be messy to buy now, but in good time it should present a great opportunity. I'll let you know.
JSE:APNLong
by Timonrosso
Aspen short looks like a Risky Biscuit - Here's whyThis one is tricky and I'd consider a medium to low probability trade. Aspen has just had a few days worth of bearish candles. Strong selling has clearly taken place. During the time, it's formed an M Formation. The price has broken below the neckline however there are danger signs that it might not work out. 1. 7>21 - Bullish. 2. Price >200 and needs to combat and break down 3. Smart Money Concepts - There is a fair value gap with an inefficiency of buying and selling. So the price is likely to go up at least 50% of the gap before choosing. 4. The JSE is in a jovial and positive mood right now... So you can see there are conflicting signals and if I had to get in, I would only risk 0.5% in this trade. RSI<50 Target R134.84 RISKY BISCUIT!
JSE:APNShort
by Timonrosso
Aspen Wedge Breakout looks promising to R194.76Falling Wedge has formed on Aspen. The price has broken out and looks like it's set to rally. A conservative trader could wait for a retest, or an impulse trader could trigger it now. 7>21>200 -Bullish RSI >50 Target - R194.76 SMC: Sell Side LIquidity Smart Money buys into positions (and sweeps liquidity) from traders who are long (get stopped) and for short traders who enter into their trades. ABOUT THE COMPANY Aspen Pharmacare is a leading global pharmaceutical company with a deep footprint in both emerging and developed markets. Founded in South Africa: Aspen Pharmacare was founded in 1850 in South Africa, starting as a single pharmacy in Durban. Global Presence: Aspen has a strong international presence, with operations in about 56 countries across six continents. Product Range: The company’s primary business is in the provision of branded and generic pharmaceutical products, as well as infant nutritionals and consumer healthcare products. Leadership: The company was co-founded by South African businessman Stephen Saad, who remains the CEO. Significant Player in ARVs: Aspen is one of the world's largest suppliers of antiretroviral (ARV) drugs for treating HIV/AIDS, contributing to the global fight against the disease. Manufacturing Prowess: Aspen owns and operates 23 manufacturing facilities across 15 sites, demonstrating its vast manufacturing capabilities.
JSE:APNLong
by Timonrosso
Aspen upcoming earningsJSE:APN mini rally following a positive trading statement quickly fizzled. Aspen JSE:APN reporters that EPS will be between 32% - 37%. Audited results are coming this week, the numbers are expected to remain the same. The share is trading below key levels, the stock will need great numbers to push the price up, a promising setup is the price trading above R160/share. Otherwise, the downtrend in the stock will continue, especially if the price drops to R136/share.
JSE:APN
by Trend_Trader_JSE